China is on the brink of a groundbreaking milestone in healthcare as its first biosimilar Ozempic drug seeks approval. This move underscores the country’s commitment to innovation and meeting the healthcare needs of its population. As China moves closer to securing approval for its biosimilar Ozempic drug, the implications for the healthcare industry are profound. The availability of biosimilars could enhance patient access to essential medications, particularly for chronic conditions like diabetes
According to a statement by news agency Reuters, the Chinese drugmaker said in a post on Wednesday on its official social media account that the drug application, Jiyoutai was for usage to control blood sugar in patients with type 2 diabetes.
Jiuyuan Gene, which is majority-owned by China’s Huadong Medicine, completed a late-stage clinical trial in China last year comparing its semaglutide injection with Ozempic in a group of 476 patients, according to a clinical trials registry. It is noteworthy that the patent of the drug is not set to expire until 2026 but is contested in court.
Jiuyuan Gene Engineering collaborated with its top shareholder Huadong Medicine to develop another diabetes drug that is approved in China.
This development aligns with China’s broader efforts to improve healthcare accessibility and affordability nationwide. Moreover, it highlights the country’s strides towards achieving self-sufficiency in pharmaceutical production and reducing dependency on imported drugs. Overall, the approval of China’s first biosimilar Ozempic drug represents a significant step forward in the nation’s healthcare journey.
read more
image source
